A 68-year-old man with acute acalculous cholecystitis (confirmed on CT) and sepsis (lactate 4.2 mmol/L, hypotension requiring vasopressors) is admitted to the ICU. He has renal impairment (creatinine 2.1 mg/dL). Which antibiotic regimen is most appropriate for this critically ill patient?

Explanation

## Antibiotic Management of Septic Acalculous Cholecystitis in the ICU ### Clinical Context This patient presents with: - **Acalculous cholecystitis** — polymicrobial infection (gram-negatives: *E. coli*, *Klebsiella*, *Pseudomonas*; anaerobes: *Bacteroides*; gram-positives including MRSA in healthcare-associated cases) - **Septic shock** (lactate 4.2 mmol/L, vasopressor-dependent) — mandates broadest empiric coverage - **Renal impairment** (creatinine 2.1 mg/dL) — limits nephrotoxic agents and alters dosing **Key Point:** For a critically ill ICU patient with septic shock and suspected ESBL/resistant gram-negative organisms, **Meropenem + Vancomycin** is the preferred empiric regimen per IDSA/SIS guidelines for complicated intra-abdominal infections in high-risk patients. --- ### Why Meropenem Over Piperacillin-Tazobactam (Option C)? Both regimens are guideline-acceptable for biliary sepsis, but meropenem is preferred in **this specific patient** for the following reasons: | Feature | Meropenem | Piperacillin-Tazobactam | |---|---|---| | ESBL-producing organisms | **Reliable coverage** | Unreliable (inoculum effect) | | *Pseudomonas aeruginosa* | Excellent | Good | | Anaerobic coverage | Yes | Yes | | Renal impairment | Dose-adjust; not nephrotoxic | Dose-adjust; not nephrotoxic | | ICU septic shock preference | **First-line** | Second-line | The MERINO trial (2018, *JAMA*) demonstrated that piperacillin-tazobactam was **inferior** to meropenem for definitive treatment of ESBL-producing *E. coli* and *Klebsiella* bacteremia (30-day mortality 12.3% vs 3.7%). In an ICU patient with septic shock, empiric carbapenem coverage is therefore preferred when ESBL risk is high (healthcare exposure, prior antibiotics, renal impairment). **Vancomycin** is added to cover MRSA, which is increasingly prevalent in healthcare-associated acalculous cholecystitis. Requires TDM with dose adjustment for renal impairment (target AUC/MIC 400–600 per updated ASHP/IDSA guidelines). --- ### Why Not the Other Options? - **Option B (Ceftriaxone + metronidazole):** Inadequate for septic shock in ICU; no *Pseudomonas* coverage; insufficient for ESBL organisms; no MRSA coverage. - **Option D (Imipenem + gentamicin):** Imipenem carries a **dose-dependent seizure risk** that is significantly amplified when creatinine >2 mg/dL (reduced renal clearance → CNS accumulation). Gentamicin is an aminoglycoside — **nephrotoxic** and contraindicated in established renal impairment. This combination is doubly dangerous in this patient. *(Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.; Harrison's Principles of Internal Medicine, 21st ed.)* --- **Clinical Pearl:** Acalculous cholecystitis in ICU patients carries 30–50% mortality. Antibiotic therapy must be paired with urgent **source control** (percutaneous cholecystostomy is preferred over surgery in unstable patients). Meropenem + vancomycin provides the broadest empiric coverage while avoiding the nephrotoxicity (gentamicin) and seizure risk (imipenem) pitfalls relevant to this patient's comorbidities. *(IDSA Guidelines for Complicated Intra-Abdominal Infections, 2010/updated; SIS/IDSA 2017)*